INT251788

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.06
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 9
Disease Relevance 7.29
Pain Relevance 0.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

ESYT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 10 88.76 High High
Central nervous system 48 82.96 Quite High
tolerance 11 74.36 Quite High
Pain 6 32.00 Quite Low
Inflammation 11 5.00 Very Low Very Low Very Low
Bioavailability 10 5.00 Very Low Very Low Very Low
cva 6 5.00 Very Low Very Low Very Low
methotrexate 6 5.00 Very Low Very Low Very Low
addiction 4 5.00 Very Low Very Low Very Low
opiate 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Advanced Or Metastatic Breast Cancer 512 100.00 Very High Very High Very High
Toxicity 236 96.00 Very High Very High Very High
Disease 256 95.64 Very High Very High Very High
Vomiting 65 94.00 High High
Exanthema 86 93.28 High High
Diarrhoea 124 92.80 High High
Cancer 399 92.40 High High
Breast Cancer 367 91.68 High High
Headache 10 88.76 High High
Dizziness 7 88.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These results suggest further investigation of tanespimycin in the treatment of HER2 over-expressed MBC patients.


Gene_expression (expressed) of MBC associated with advanced or metastatic breast cancer
1) Confidence 0.06 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 1.52 Pain Relevance 0.09
In preliminary findings from a phase II study of combined trastuzumab and pertuzumab in patients with HER2-overexpressed MBC, a 40% CB rate with multiple complete responses and PRs was described [85].


Gene_expression (overexpressed) of MBC associated with advanced or metastatic breast cancer
2) Confidence 0.03 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2972555 Disease Relevance 0.79 Pain Relevance 0.04
In this group of heavily pretreated patients (76% of whom received four or more lines of prior therapy), lapatinib had modest activity in HER2-overexpressed MBC.
Gene_expression (overexpressed) of MBC associated with advanced or metastatic breast cancer
3) Confidence 0.03 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2972555 Disease Relevance 0.79 Pain Relevance 0
Lapatinib was approved by the US Food and Drug Administration in 2007 for use in combination with capecitabine for treatment of HER2-overexpressed MBC that had progressed with standard treatment [61].
Gene_expression (overexpressed) of MBC associated with advanced or metastatic breast cancer
4) Confidence 0.03 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2972555 Disease Relevance 0.82 Pain Relevance 0
The large, ongoing Aphrodite trial has a target population of 8,000 patients with HER2-overexpressed MBC.
Gene_expression (overexpressed) of MBC associated with advanced or metastatic breast cancer
5) Confidence 0.03 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2972555 Disease Relevance 0.58 Pain Relevance 0.03
The large, ongoing Aphrodite trial has a target population of 8,000 patients with HER2-overexpressed MBC.
Gene_expression (-) of MBC associated with advanced or metastatic breast cancer
6) Confidence 0.03 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2972555 Disease Relevance 0.58 Pain Relevance 0.03
In this group of heavily pretreated patients (76% of whom received four or more lines of prior therapy), lapatinib had modest activity in HER2-overexpressed MBC.
Gene_expression (-) of MBC associated with advanced or metastatic breast cancer
7) Confidence 0.03 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2972555 Disease Relevance 0.79 Pain Relevance 0
A current trial is prospectively assessing first-line lapatinib and weekly paclitaxel 80 mg/m2 in HER2-positive MBC.


Gene_expression (positive) of MBC associated with advanced or metastatic breast cancer
8) Confidence 0.02 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.34 Pain Relevance 0
A prospective phase III study confirms superiority of letrozole and lapatinib over letrozole alone in HER2-positive MBC.
Gene_expression (positive) of MBC associated with advanced or metastatic breast cancer
9) Confidence 0.02 Published 2010 Journal Cancer management and research Section Abstract Doc Link PMC3004582 Disease Relevance 1.09 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox